[1]华夏,李广兴,刘仲涛,等.贝伐单抗联合放化疗对脑胶质瘤的临床疗效分析[J].临床神经外科杂志,2019,16(3):254-258.[doi:10.3969/j.issn.1672-7770.2019.03.015]
 HUA Xia,LI Guang-xing,LIU Zhong-tao,et al.Clinical efficacy and prognosis of glioma treated with bevacizumab combined with radiotherapy[J].Journal of Clinical Neurosurgery,2019,16(3):254-258.[doi:10.3969/j.issn.1672-7770.2019.03.015]
点击复制

贝伐单抗联合放化疗对脑胶质瘤的临床疗效分析()
分享到:

《临床神经外科杂志》[ISSN:1672-7770/CN:32-1727/R]

卷:
16
期数:
2019年第3期
页码:
254-258
栏目:
论著
出版日期:
2019-06-15

文章信息/Info

Title:
Clinical efficacy and prognosis of glioma treated with bevacizumab combined with radiotherapy
作者:
华夏李广兴刘仲涛牛占锋郜彩斌
750003 银川,宁夏医科大学总医院神经外科
Author(s):
HUA Xia LI Guang-xing LIU Zhong-taoet al.
Department of Neurosurgery, Ningxia Medical University General Hospital, Yinchuan 750003, China
关键词:
脑胶质瘤贝伐单抗放疗近期疗效免疫水平毒副反应
Keywords:
glioma bevacizumab radiotherapy recent efficacy immunity toxicity
分类号:
R739.41
DOI:
10.3969/j.issn.1672-7770.2019.03.015
文献标志码:
A
摘要:
【摘要】目的 探讨贝伐单抗联合放疗对脑胶质瘤的临床效果及预后改善。方法选择2014年8月—2017年12月收治的60例脑胶质瘤患者,根据术后治疗方案不同分为对照组(30例)和贝伐单抗组(30例)。对照组采用单纯放疗联合替莫唑胺治疗,贝伐单抗组在对照组的治疗基础上再联合贝伐单抗治疗。两组患者均进行1个月治疗,治疗后观察近期临床疗效。治疗前、后检测血T淋巴细胞水平。治疗后对患者进行随访3年,比较两组患者的预后。结果贝伐单抗组的近期有效率为46.7%,高于对照组的26.7%(P<0.05)。两组治疗后血CD+3、CD+4、CD+4/CD+8水平均高于治疗前(均P<0.05);CD+8水平低于治疗前(均P<0.05)。贝伐单抗组治疗后CD+3、CD+4、CD+4/CD+8水平均高于对照组(均P<0.05),CD+8水平低于对照组(P<0.05)。两组连续治疗1个月的毒副反应(骨髓抑制、胃肠道反应、高血压、出血、乏力及感染)发生率比较,差异无统计学意义(均P>0.05)。贝伐单抗组患者的中位无进展生存时间为(6.85±1.21)个月,中位总生存期为(9.89±2.41)个月,均分别长于对照组的(4.12±0.89)个月和(7.27±2.08)个月(均P<0.05)。结论将贝伐单抗联合放疗用于治疗脑胶质瘤,有助于提高近期疗效,改善机体免疫水平,不增高毒副反应发生率,能延长患者的无进展生存时间和总生存期,值得临床推广应用。
Abstract:
Abstract: ObjectiveTo investigate the clinical effect and outcome improvement of bevacizumab combined with radiotherapy in neuroglioma. MethodsA total of 60 neurological glioma patients admitted to hospital from August 2014 to December 2017 were selected and divided into control group(n=30) and experimental group(n=30) according to treatment options. The control group was treated with radiotherapy combined with temozolomide alone. The experimental group was treated with bevacizumab on the basis of the control group. Both groups were treated for 1 month. After the treatment, patients were followed for 3 years. Clinical efficacy and prognosis of the two groups were compared. ResultsThe short-term efficacy rate was 46.67% in the experimental group treated with bevacizumab combined with radiotherapy for 1 month, which was higher than that in the control group(26.67%) (P<0.05). CD+3, CD+4, and CD+4were obtained 1 month after the treatment in the experimental group and control group. The level of CD+8was higher than before treatment(P<0.05) and the level of CD+8was lower in the experimental group and control group at 1 month after treatment than that before treatment(P<0.05). CD+3, CD+4, and CD+4were measured at 1 month after treatment in the experimental group. The levels of CD+8were significantly higher in the experimental group than in the control group(P<0.05). There was no statistically significant difference in the incidence of hypertension, bleeding, fatigue, and infection between two groups(P>0.05). In the bevacizumab group, the median progressive survival time was(6.85±1.21) months, and the total median survival time was(9.89 ±2.41) months. They were longer than the control group (4.12 ±0.89) months and (7.27 ±2.08) months (all P<0.05). ConclusionThe combination of bevacizumab and radiotherapy in brain glioma is helpful to improve the short-term efficacy, improve the immune level of the body, not increase the incidence of toxic side effects, and prolong the progressive survival time and the total survival time of the patients. It is worth popularizing and applying in clinic.

相似文献/References:

[1]张贺春,窦长武,牛丽丽.Survivin拮抗肽对C6大鼠胶质瘤细胞作用的实验研究[J].临床神经外科杂志,2015,(03):227.
[2]项威,陈东,胡继良,等.贝伐单抗联合化疗治疗复发高级别胶质瘤疗效观察及安全性分析[J].临床神经外科杂志,2015,(04):269.
[3]赵伟,张旭,陆冬,等.Snail介导GOLPH3对人脑胶质瘤细胞迁移和侵袭作用的研究[J].临床神经外科杂志,2015,(05):341.
[4]苗发安,陈晨,范月超.端粒结合蛋白-1在脑胶质瘤中的表达及临床意义[J].临床神经外科杂志,2014,(02):94.
[5]宋振,高恒.CCN即早基因家族在脑胶质瘤发生机制中的研究进展[J].临床神经外科杂志,2014,(02):153.
[6]蒋伟峰,高方友.白细胞介素-17及其受体在脑胶质瘤中的表达研究进展[J].临床神经外科杂志,2014,(02):156.
[7]刘翔宇,孙康健,王汉东,等.荧光实时监测贝伐单抗治疗胶质母细胞移植瘤的实验研究[J].临床神经外科杂志,2016,(02):110.
 LIU Xiang-yu,SUN Kang-jian,WANG Han-dong,et al.Bioluminescent imaging of the impact of bevacizumab on anti-proliferation and angiogenesis in human glioblastomaxenografts in vivo[J].Journal of Clinical Neurosurgery,2016,(3):110.
[8]徐拓野,于震男,赵鹏来,等.NUSAP1在脑胶质瘤中的表达以及对胶质瘤细胞LN229功能的影响[J].临床神经外科杂志,2016,(02):122.
 XU Tuo-ye,YU Zhen-nan,ZHAO Peng-lai,et al.Expression of NUSAP1 in glioma cells and its effects on LN229 cell[J].Journal of Clinical Neurosurgery,2016,(3):122.
[9]王大成,刘雪娇,刘宁,等.转录因子FOXR2对脑胶质瘤细胞增殖的影响[J].临床神经外科杂志,2016,(05):321.
 WANG Da-cheng,LIU Xue-jiao,LIU Ning,et al.Effects of FOXR2 on proliferation of glioma cells[J].Journal of Clinical Neurosurgery,2016,(3):321.
[10]马亮,傅相平,赵明,等.伽玛刀联合贝伐单抗治疗颅内恶性胶质瘤的疗效分析[J].临床神经外科杂志,2016,(05):328.
 MA Liang,FU Xiang-ping,ZHAO Ming,et al.Outcome analysis of gamma knife and bevacizumab against intracranial malignant gliomas[J].Journal of Clinical Neurosurgery,2016,(3):328.

更新日期/Last Update: 2019-06-15